AIM ImmunoTech CEO op-ed touts Ampligen as biodefense antiviral; cites 100% Ebola survival in mouse model

AIM ImmunoTech Inc.

CEO Thomas K. Equels published op-ed in Breaking Defense on Aug 11, 2026 promoting Ampligen (rintatolimod) as broad-spectrum antiviral.
USAMRIID preclinical study cited: 100% survival in rintatolimod-treated Ebola mouse cohort vs 100% mortality in controls (Antiviral Research).
Company seeking government support for further Ebola/Bundibugyo and coronavirus mechanism studies; cites Utah State SARS research.
Disclosure: Ampligen not FDA-approved for Ebola, Bundibugyo, coronaviruses or any biodefense indication.
Op-ed references ~1,200 COVID infections aboard USS Theodore Roosevelt to argue for biodefense preparedness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.